Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus TRAVOPROST.
TRAVATAN vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."